Fierce Pharma
OCTOBER 7, 2024
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.
Bio Pharma Dive
OCTOBER 7, 2024
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 7, 2024
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.
Bio Pharma Dive
OCTOBER 7, 2024
Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 7, 2024
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
Bio Pharma Dive
OCTOBER 7, 2024
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 7, 2024
The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.
Pharmaceutical Technology
OCTOBER 7, 2024
US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker struggles with its post-pandemic financial performance.
Bio Pharma Dive
OCTOBER 7, 2024
Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.
Fierce Pharma
OCTOBER 7, 2024
After winning a first-in-class nod for its two-drug inhaler Airsupra l | After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity.
Pharma Times
OCTOBER 7, 2024
Biotech company moves forward with phase 2 trial for precision cancer surgery
Pharmaceutical Technology
OCTOBER 7, 2024
The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.
Deltaclinical
OCTOBER 7, 2024
Would you like to learn more about our services? Visit us at booth C-24. We are happy to welcome you! But first, our CEO Geert Briers will attend the EU-Japan center conference in Osaka from 7 – 8 OCT.
Pharmaceutical Technology
OCTOBER 7, 2024
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
OCTOBER 7, 2024
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
Pharmaceutical Technology
OCTOBER 7, 2024
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.
Pharma Times
OCTOBER 7, 2024
Scottish Medicines Consortium recommends pembrolizumab
Pharmaceutical Technology
OCTOBER 7, 2024
mRNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in precision medicine.
pharmaphorum
OCTOBER 7, 2024
The recent Mpox outbreak highlights the urgent need for new approaches to therapeutic antibody research. Discover how the World Health Organization (WHO) and CDC are responding to this public health crisis.
Pharmaceutical Technology
OCTOBER 7, 2024
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity
pharmaphorum
OCTOBER 7, 2024
Learn how accessible technology support can help in managing the UK's ADHD medication supply crisis within the NHS, and improve outcomes for patients.
Drug Patent Watch
OCTOBER 7, 2024
Pharmacokinetics (PK) plays a crucial role in the development and approval of generic drugs. PK studies help ensure that generic drugs are bioequivalent to their brand-name counterparts, meaning they have similar absorption, distribution, metabolism, and excretion (ADME) profiles.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
OCTOBER 7, 2024
Victor Ambros and Gary Ruvkun have shared this year's Nobel Prize in Physiology or Medicine for their discovery of microRNA
Fierce Pharma
OCTOBER 7, 2024
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.
pharmaphorum
OCTOBER 7, 2024
Stay updated on the latest advancements in early detection and innovative therapies targeting tau pathology in Alzheimer’s disease. Learn more about the cutting-edge research and treatments available.
Drug Channels
OCTOBER 7, 2024
Informa Connect’s PBM Contracting Summit December 10-11, 2024 | Chicago, IL Drug Channels readers save 10% with code 24DRCH10 * Experts from across the US come together each year at the PBM Contracting Summit to gain innovative and practical contracting strategies, master PBM innovation and design, improve patient care management and rising costs, understand the current legislative issues impacting contract negotiations and more.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 7, 2024
UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific researchers, taking on some of the responsibility held by GPs. The minister told the Royal College of General Practitioners (RCGP) annual conference that, while many UK patients have given their consent for their data to be shared with studies run by the likes of the UK Biobank, Genomics England, and Our Future Health, they "still see, far too often, that this data is not shared
Pharmaceutical Commerce
OCTOBER 7, 2024
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, explains how pending legislation can improve patient access, and how these are helping with recognizing pharmacists as HCPs.
pharmaphorum
OCTOBER 7, 2024
Learn how Oliver Stohlmann nurtures the mentor in you, emphasising values like integrity. Discover how you can become a mentor and make a difference in someone's life.
Intouch Solutions
OCTOBER 7, 2024
How does your organization make marketing decisions? Artificial intelligence (AI) is revolutionizing the way pharmaceutical companies make marketing decisions, and EVERSANA INTOUCH is at the forefront of this transformation. In this POV, John Kenny, EVP and Head of Strategic Planning, delves into the innovative use of AI-powered personas to keep the customer’s perspective central in marketing strategies.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
124 
Let's personalize your content